New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
MannKind Corporation (MNKD) vs Taysha Gene Therapies, Inc. (TSHA)
- MannKind Corporation MNKD 3.91 −0.76%
- Taysha Gene Therapies, Inc. TSHA 3.71 −1.59%
MannKind Corporation and Taysha Gene Therapies, Inc. are both Biotechnology companies. MannKind Corporation and Taysha Gene Therapies, Inc. are of similar size ($1.4B and $1.3B). MannKind Corporation grew revenue faster over the last twelve months: 31.7% against 19.0%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −18.1%) and the higher return on invested capital (0.00% vs −2.58%). Across the 16 metrics below, MannKind Corporation leads on 8 and Taysha Gene Therapies, Inc. on 8.
Valuation
Profitability
| Metric | MNKD | TSHA | Biotechnology median |
|---|---|---|---|
| Gross margin | 75.76% | 100.00% | 70.18% |
| Operating margin | (2.88%) | 0.00% | 0.00% |
| Net margin | (18.10%) | 0.00% | 0.00% |
| Free cash flow margin | (18.97%) | 0.00% | 0.00% |
| Return on equity | 182.90% | (54.18%) | (51.58%) |
| Return on assets | (12.29%) | (41.52%) | (45.91%) |
| Return on invested capital | (2.58%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack